I think in the majority of cases, because of preferential pricing, there exist either at cost or below cost in the least developed countries. They're usually either at cost or have a very small markup in the developing or more developed countries, with the anticipation that in the developed world they're going to pay the full price.
So as long as we encourage a preferential pricing system where the products don't get diverted back into developed markets, I think the industry is willing to come to the table. But what you're talking about is increasing this global pool of funding to purchase pharmaceutical products. That can be brand or generic. I think there would be certainly an interest in doing that, but I can't speak on behalf of the government's willingness to do that.